Can I read Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) on EtoBox?

Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) by David J. Adelstein; James Moon; Ehab Hanna; P. G. Shankar Giri; Glenn M. Mills; Gregory T. Wolf; Susan G. Urba is a Medicine article available to read on EtoBox.

What is Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) about?

## Abstract ## Background In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single‐agent cisplatin. ## Methods Two induction courses using docetaxel (75 mg/m^2^ on day 1), cisplatin (100 mg/m^2^ on day 1), and fluorouracil (1000 mg/m^2^/day continuous intravenous infusion days 1–4) were given, with an interval of 21 days. Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m^2^) on days 1 and 22 of radiation. ## Results There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease. At least 1 grade 3‐4 toxicity was experienced by 63 patients (85%) during induction. A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment. At least 1 grade 3‐4 toxicity was noted in 53 of the 58 pati

Who reads Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)?

Author

David J. Adelstein; James Moon; Ehab Hanna; P. G. Shankar Giri; Glenn M. Mills; Gregory T. Wolf; Susan G. Urba

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley; Research Square (ISSN 1043-3074)

Published

2009

Language

EN

Field

Medicine (Health Sciences)